Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

Analysis of the Clinical Characteristics and Three Treatment Methods of Granulomatous Lobular Mastitis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - non-lactating and aged 15-65 years - histopathological confirmation of GLM - normal liver and kidney function Who Should NOT Join This Trial: - lactating and pregnant women - allergies to rifampin, isoniazid, or ethambutol - concurrent malignant breast tumors - severe underlying diseases - other conditions deemed unsuitable by the investigator and - refusal to participate in the study Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * non-lactating and aged 15-65 years * histopathological confirmation of GLM * normal liver and kidney function Exclusion Criteria: * lactating and pregnant women * allergies to rifampin, isoniazid, or ethambutol * concurrent malignant breast tumors * severe underlying diseases * other conditions deemed unsuitable by the investigator and * refusal to participate in the study

Treatments Being Tested

PROCEDURE

Surgery

patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.

DRUG

triple anti-tuberculosis drug

Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).

Locations (1)

First affiliated hospital of Harbin medical university
Harbin, Heilongjiang, China